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Previous analyses have shown that estimated
ambient concentrations of acrolein, a Clean
Air Act hazardous air pollutant, are above 
levels of concern for noncancer health effects
(Caldwell et al. 1998; Tam and Neumann
2004; Woodruff et al. 1998). Estimated
ambient concentrations of acrolein exceed the
reference concentration (RfC) in > 90% of
the 60,000 continental U.S. census tracts for
1990 and 1996; the RfC was exceeded in
> 90% of urban census tracts in 1999 [U.S.
Environmental Protection Agency (EPA)
2006; Woodruff et al. 1998]. Estimated
acrolein concentrations in 1996 and 1999
exceeded 10 times the RfC in > 10% of U.S.
census tracts (U.S. EPA 2006). Absent any
further regulatory controls, the average ambi-
ent concentration of acrolein in the United
States in 2030 is projected to be more than
three times the RfC (Cook et al. 2006). The
RfC is defined as an estimate of continuous
inhalation exposure to the human population,
including sensitive subgroups, which is likely
to be without appreciable risk of deleterious
effects over a lifetime (U.S. EPA 2005b).
In humans, acute acrolein exposure pro-
duces eye, nose, and throat irritation
(Esterbauer et al. 1991; Sim and Pattle 1957;
Weber-Tschopp et al. 1977). Acrolein expo-
sure is also recognized to exacerbate asthma
(Leikauf 2002); toxicology studies have shown
that acrolein exposure results in increased
apoptosis of alveolar macrophages (Li et al.
1997), inhibition of neutrophil apoptosis
(Finkelstein et al. 2001), increased mucus
secretion (Borchers et al. 1999), increased pul-
monary edema (Hales et al. 1989; Kutzman
et al. 1985), and increased bronchial respon-
siveness (Ben-Jebria et al. 1994; Leikauf et al.
1989). The current chronic inhalation RfC
for acrolein is 2 × 10–5 mg/m3, based on nasal
lesions in rats (U.S. EPA 2003a). Roughly
three-fourths of ambient acrolein is estimated
to originate from mobile sources (U.S. EPA
2002a), with the remainder from agriculture,
industrial processes, tobacco smoke, and forest
fires (U.S. EPA 2003b). 
Although the RfC for acrolein is based on
respiratory system impairment, conventional
risk assessment methods applied to animal
data do not provide estimates of potential
incidence or severity of adverse effects. For
example, no particular level of risk is associ-
ated with the RfC itself, and interpretation of
the significance of concentrations either
above or below the RfC is not clear. Except
for some environmental contaminants with
extensive epidemiologic data, current risk
assessment methods for noncancer effects are
not amenable to quantifying estimates of
potential health effects. 
To further elucidate the potential respira-
tory risks associated with airborne acrolein,
we used benchmark dose modeling (BMD) to
estimate the probability of respiratory effects
at ambient concentrations of acrolein. 
Methods
Data selection. We reviewed the toxicologic
literature to identify data amenable to
dose–response modeling, using criteria out-
lined by the U.S. EPA in its draft Benchmark
Dose Technical Guidance Document (U.S.
EPA 2000). These criteria include the pres-
ence of a graded monotonic response with
dose and a significant dose-related trend in
the selected end point(s) (U.S. EPA 2000).
Some of the identified studies did not have
sufficient incidence data for modeling (Leach
et al. 1987; Lyon et al. 1970). Of the other
available studies (Cassee et al. 1996; Costa
et al. 1986; Feron et al. 1978; Kutzman et al.
1984, 1985), we selected a data set from
Costa et al. (1986), which had a statistically
significant dose–response relationship
between acrolein exposure and both specific
compliance (sCL), calculated as dynamic
compliance divided by forced residual capac-
ity, and the ratio of residual volume to total
lung capacity (RV/TLC). Both sCL and
RV/TLC are normalized to an individual ani-
mal’s lung size, which corrects for inter-
individual variability due to size for these
measures. 
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BACKGROUND: Estimated ambient concentrations of acrolein, a hazardous air pollutant, are greater
than the U.S. Environmental Protection Agency (EPA) reference concentration throughout the
United States, making it a concern for human health. However, there is no method for assessing
the extent of risk under the U.S. EPA noncancer risk assessment framework. 
OBJECTIVES: We estimated excess risks from ambient concentrations of acrolein based on dose–
response modeling of a study in rats with a relationship between acrolein and residual volume/total
lung capacity ratio (RV/TLC) and specific compliance (sCL), markers for altered lung function. 
METHODS: Based on existing literature, we defined values above the 90th percentile for controls as
“adverse.” We estimated the increase over baseline response that would occur in the human popula-
tion from estimated ambient concentrations of acrolein, taken from the U.S. EPA’s National-Scale
Air Toxics Assessment for 1999, after standard animal-to-human conversions and extrapolating to
doses below the experimental data. 
RESULTS: The estimated median additional number of adverse sCL outcomes across the United
States was approximately 2.5 cases per 1,000 people. The estimated range of additional outcomes
from the 5th to the 95th percentile of acrolein concentration levels across census tracts was
0.28–14 cases per 1,000. For RV/TLC, the median additional outcome was 0.002 per 1,000, and
the additional outcome at the 95th percentile was 0.13 per 1,000.
CONCLUSIONS: Although there are uncertainties in estimating human risks from animal data, this
analysis demonstrates a method for estimating health risks for noncancer effects and suggests that
acrolein could be associated with decreased respiratory function in the United States. 
KEY WORDS: acrolein, dose response, hazardous air pollutants (HAPs), noncancer risk assessment,
respiratory function. Environ Health Perspect 115:410–415 (2007). doi:10.1289/ehp.9467 available
via http://dx.doi.org/ [Online 11 December 2006]
Full details of the study by Costa et al. are
reported elsewhere (1986). Briefly, male
Fischer-344 rats were exposed to 0.0, 0.4, 1.4,
and 4.0 ppm concentrations of acrolein vapors
for 62 days (6 hr/day, 5 days/week). Following
exposure, the researchers conducted lung
function analyses on 24, 23, 21, and 9 rats
from the low to high exposure groups, respec-
tively. The number in the highest dose group
was reduced because of high mortality rates
(65%) during the experiment; there was no
mortality in the other dose groups. There was
an additional animal in the 1.4-ppm dose
group; however, data on outcomes of interest
were not available for this animal, and so it was
not included in the present analysis. Residual
volume, total lung capacity, and forced residual
capacity all significantly increased with increas-
ing acrolein exposure; sCL and RV/TLC also
changed significantly with increasing acrolein
exposure (Costa et al. 1986). Data from the
study were obtained from the authors, and are
summarized in Table 1.
Model development. We converted acrolein
concentrations used by Costa et al. (1986) into
human equivalent concentrations (HEC) by
converting from intermittent exposure to
continuous exposure, from shorter to longer
duration of exposure, and from rat physiology
to human physiology (Supplemental Material
available online at http://www.ehponline.
org/docs/2006/9467/suppl.pdf). Conversions
were based on standard U.S. EPA practice
and estimates the U.S. EPA has used previ-
ously for acrolein (U.S. EPA 2003b). These
HEC values were modeled separately with the
two lung function parameters from Costa
et al. (1986) using the U.S. EPA’s Benchmark
Dose Software (BMDS), version 1.3.2, in
accordance with the U.S. EPA’s draft BMD
technical guidance document (U.S. EPA
2000). We fit three types of models supported
by the BMDS (linear, polynomial, and
power) to determine the best-fitting model
type. Several criteria were used to determine
the best-fitting model, including graphical
displays of predicted responses, likelihood
ratio tests for model fit, Akaike’s information
criterion values, and chi-square residual values
at lower experimental doses (Supplemental
Material available online at http://www.
ehponline.org/docs/2006/9467/suppl.pdf). 
Defining change in continuous end points.
Among a group of individuals, measurements
of continuous end points such as ratios of
lung function parameters or blood pressure
produce a range of values due to inter-
individual variation; collectively, these varia-
tions result in a distribution of response for
the population. Exposure to a toxicant that
causes a change in this response will essen-
tially shift the mean and potentially the vari-
ance of the resulting response distribution, as
shown in Figure 1. 
To estimate additional adverse outcomes,
or the number of adverse outcomes attribut-
able to acrolein exposure, we need to define
what magnitude of a lung function parameter
to consider “adverse” (Crump 1995; Gaylor
and Slikker 1990; U.S. EPA 2000). After
defining the adverse outcome level cutoff
(such as level “A” in Figure 1), we can esti-
mate how many individuals in the baseline
population are expected to respond at or
above this value, and for a population with an
increased exposure to a contaminant, the
increase in the number of individuals with
adverse outcomes over baseline (Figure 1).
There is currently no defined standard for
adverse or abnormal levels in sCL and
RV/TLC, either in rats or humans. Therefore,
we chose two different approaches to estimate
adverse health effects. For the first, we defined
the baseline adverse outcome prevalence as
values ≥ 90th percentile of the control
response distribution. Therefore, 10% of
unexposed individuals would, by definition,
experience adverse outcomes. We refer to this
baseline adverse response level as the “adverse
cutoff 10” (AC10). To estimate the potential
effect of acrolein exposure, we estimated the
number of additional adverse outcomes
expected at a given exposure level. We chose
the 90th percentile as our definition of
adverse based on consideration of other pub-
lic health end points. For example, small for
gestational age babies are most often defined
as those whose birth weight is < 10th per-
centile of babies with the same gestational age
(Tambyraja and Ratnam 1982). For the sec-
ond approach, we estimated the relative
change in lung function parameters following
acrolein exposure by determining the relative
excess response over baseline mean. 
Estimating additional adverse outcomes.
We used methods based on previous work to
calculate additional adverse outcomes from
continuous, noncancer outcomes (Gaylor and
Slikker 1990; Kodell et al. 1995; U.S. EPA
2000). Visually, this value is the difference in
the areas between the response distribution
curves for exposed and nonexposed popula-
tions (Figure 1). This area is determined by
converting the response distributions into a
standard normal scale and using standard
normal deviate (z) values to identify their
associated probability, or area under the curve. 
We defined p as the proportion of non-
adversely affected individuals in the control
population (here, defined at 0.90) and r as the
proportion of individuals with an adverse out-
come in the exposed population. The term r
can be determined using the equation
k = zp–z(p–r), where zp is the standard normal
Estimating risk from ambient acrolein
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Table 1. Summary of lung function data (mean ± SD) from Costa et al. (1986).
Acrolein concentration in air (ppm)
All 0.0 0.4 1.4 4.0
Measure (n = 77) (n = 24) (n = 23) (n = 21) (n = 9) 
RV (cm3) 1.67 (1.02) 1.34 (0.57) 1.46 (0.86) 1.51 (0.53) 3.48 (1.39)
TLC (cm3) 10.74 (1.93) 10.13 (1.02) 9.97 (1.05) 10.57 (1.24) 14.71 (2.17)
RV/TLC 0.15 (0.06) 0.13 (0.05) 0.14 (0.07) 0.14 (0.04) 0.23 (0.06)
Cdyn (cm H2O–1) 0.23 (0.08) 0.24 (0.07) 0.24 (0.10) 0.20 (0.06) 0.26 (0.10)
FRC (cm3) 3.55 (1.43) 3.06 (0.46) 3.06 (0.40) 3.26 (0.56) 6.81 (1.97)
sCL (cm3/cm H2O) 0.07 (0.03) 0.08 (0.03) 0.08 (0.03) 0.06 (0.02) 0.04 (0.02)
Abbreviations: Cdyn, dynamic compliance; FRC, functional reserve capacity.
Figure 1. Example of the response distribution among a baseline or unexposed population (solid line) and
an exposed population (dashed line). The arrow indicates the change in mean response between the
baseline and the exposed populations. Shaded areas represent the proportion of the population with a
response past a level “A” that is considered abnormal. 
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deviate of the cumulative proportion of non-
adversely affected individuals among controls,
z(p–r) is the standard normal deviate for the
cumulative proportion of nonadversely affected
individuals among the exposed population,
and k is the multiplier of the standard normal
deviate of the increase in mean response, which
can be determined from the model for each
exposure concentration of interest. 
A sample adverse outcome calculation is
available in the Supplemental Material (http://
www.ehponline.org/docs/2006/9467/
suppl.pdf). Calculating within and below the
range of the experimental data, we assumed a
linear relationship between exposure and
response. This is similar to what is assumed in
cancer risk extrapolation below the experimen-
tal data (U.S. EPA 2005a). 
We performed a sensitivity analysis of these
results by recalculating the prevalence of
adverse outcomes among an unexposed popu-
lation as being either 2% (AC2) or 18%
(AC18) of the population. Briefly, this corre-
sponds to responses at or above the 98th per-
centile and 82nd percentile, respectively, of the
response distribution. The 98th percentile was
chosen because this is typically used by the
U.S. EPA for continuous response data (U.S.
EPA 2000), and the 82nd percentile was cho-
sen because it is the equivalent distance from
the 90th percentile, but in the opposite direc-
tion. For sensitivity analyses, we repeated the
calculations using p = 0.98, zp = 2.05 for the
AC2 and p = 0.82, zp = 0.915 for the AC18. 
We performed a second sensitivity analysis
to examine the effect on the results by elimi-
nating the highest dose group in the dose–
response modeling. About 60% of the animals
died in this group, indicating that the lung
function response could be affected by an
overwhelming toxicologic response. 
Estimating relative excess response. In the
second analysis, the relative excess response for
lung function parameter compared to baseline
was calculated from the fitted linear dose–
response function. The adjusted estimated
ambient acrolein exposure levels were used in
the selected models (Supplemental Material,
Table S2, available online at http://www.
ehponline.org/docs/2006/9467/suppl.pdf) to
predict the lung function parameters expected
following acrolein exposure, or the predicted
response. The relative excess response was
found by subtracting the baseline response
from the predicted response and then dividing
the result by the baseline response. The base-
line response is defined as the predicted mean
lung function parameter ratio at 0.0 ppm
acrolein, or 0.08 cm3/cm H2O for sCL and
0.136 (no units) for RV/TLC. 
Ambient concentrations. We used publicly
available data of estimated ambient acrolein
concentrations from the U.S. EPA’s 1999
National-Scale Air Toxics Assessment (U.S. EPA
2006) to estimate responses to acrolein at
ambient concentrations found within the
United States. Methodologic details regarding
these ambient concentration estimates are fur-
ther described in the National-Scale Air Toxics
Assessment (U.S. EPA 2006). Briefly, concen-
trations were estimated by developing a
national inventory of emissions for 1999,
which was then used as input to an atmos-
pheric dispersion model (Rosenbaum et al.
1999) that estimated average concentrations
for 1999 for each census tract in the United
States. Census tracts vary in physical size, but
generally contain populations of 4,000–5,000
individuals each. 
We used the 5th, 10th, 25th, 50th, 75th,
90th, and 95th percentiles of estimated
acrolein concentrations for all, urban, and
rural census tracts in the United States to esti-
mate the variation in risks due to acrolein
across the country. 
The distribution of 1999 annual ambient
acrolein concentrations is presented in Table 2.
Annual ambient acrolein concentrations
exceeded the current RfC for acrolein in
> 75%, 90%, and 50% of all U.S. census
tracts, census tracts within urban counties, and
census tracts within rural counties, respectively. 
Results 
Using criteria described elsewhere (U.S. EPA
2000), we selected a linear model (for sCL)
and a power model (for RV/TLC) as the best-
fitting models. Figure 2 displays a plot of
model fit and the summary data from Costa
et al. (1986). Details of the modeling results
are discussed in the Supplemental Material
(Table S1; available online at http://www.
ehponline.org/docs/2006/9467/suppl.pdf). 
Figure 3 shows the distribution of addi-
tional adverse outcomes following exposure to
acrolein for the entire U.S. population and for
those living in urban or rural census tracts.
Estimated ambient acrolein levels are signifi-
cantly higher in urban areas than in rural areas
(p < 0.04). A larger change was observed for
sCL compared to RV/TLC. We estimated that
across the United States in 1999, the median
additional adverse outcome was approximately
2.5 per 1,000 for sCL and 0.002 per 1,000 for
RV/TLC. Among urban counties, the median
estimated excess number of adverse outcomes
is 3.1 per 1,000 for sCL and 0.003 per 1,000
for RV/TLC. Among rural counties, these
numbers are 0.66 per 1,000 for sCL.
Additionally, the range of additional adverse
Woodruff et al.
412 VOLUME 115 | NUMBER 3 | March 2007 • Environmental Health Perspectives
Table 2. Estimated acrolein concentrations (µg/m3)
across the United States in 1999.a
National Urban Rural 
Percentile average counties counties 
5 0.0087 0.017 0.0034
10 0.015 0.027b 0.0054
25 0.034b 0.052b 0.011
50 0.077b 0.094b 0.021b
75 0.14b 0.16b 0.035b
90 0.26c 0.29c 0.061b
95 0.41c 0.44c 0.091b
aData from U.S. EPA’s 1999 National-Scale Air Toxics
Assessment (U.S. EPA 2006). bValue > RfC. cValue > 10
times higher than the RfC for acrolein (0.02 µg/m3).
Figure 2. Summary of data from Costa et al. (1986) and model fit for sCL (cm3/cm H2O) (A) and RV/TLC
(B) for rats in HEC. Error bars indicate 1 SD. The dashed lines represent regression lines from our fitted
models: y(x) = 0.08–0.005x for sCL; y(x) = 0.136 + 0.0005x2.63 for RV/TLC.
Acrolein (μg/m3)
sC
L (
cm
3 /c
m
 H
20
)
0.15
0.10
0.05
0.00
0 2 4 6 0 2 4 6 8
Acrolein (μg/m3)
0.30
0.20
0.10
0.00
RV
/T
LC
A B
Figure 3. Distribution of additional estimated adverse response (per 1,000) to ambient acrolein using the
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outcomes in areas between the 5th and the
95th percentiles of acrolein distribution across
census tracts would be 0.28–14 per 1,000 for
sCL and 0–0.13 per 1,000 for RV/TLC in all
counties, 0.57–15 per 1,000 for sCL and
0–0.16 per 1,000 for RV/TLC in urban coun-
ties, and 0.11–3 per 1,000 for sCL and essen-
tially zero for RV/TLC in rural counties. For
sCL, about 25% percent of U.S. census tracts
have an additional adverse outcome prevalence
of ≥ 4.6 per 1,000, and about 10% have an
estimate of risk of ≥ 8.6 per 1,000. 
The estimated additional adverse outcome
prevalence per 1,000 people varied when the
AC2 or AC18 were used. For sCL, the median
amount of additional adverse outcomes using
the AC2 and AC18, respectively, were 0.38 and
3.7 per 1,000 for all counties, 0.48 and 4.6 per
1,000 for urban counties, and 0.10 and 0.99
per 1,000 for rural counties. We found no
change in RV/TLC for any county type when
the AC2 was used, and only minimal changes
were observed among urban and all counties
when using AC18. The full range of additional
outcomes resulting from the use of these defini-
tions for adverse effect for the distribution of
acrolein exposures across the United States are
presented in the Supplemental Material
(Table S2; available online at http://www.
ehponline.org/docs/2006/9467/suppl.pdf).
We also evaluated the effect on the dose
response of eliminating the highest dose group,
because there was substantial mortality in this
group. Without the high dose group, there was
inadequate fit of the RV/TLC response for
modeling. The dose–response model for sCL
was similar to that with the high dose group,
though the slope was slightly steeper. Using the
AC10 definition for adverse outcome with this
model, we found a median additional adverse
outcome of 4.2 per 1,000 people among all
counties, 5.2 per 1,000 among urban counties,
and 1.1 per 1,000 among rural counties. Also
according to this alternative model, the range
of median additional adverse outcomes
between counties at the 5th and 95th per-
centiles of ambient acrolein exposure in 1999
was 0.48–24 per 1,000 individuals.
The estimated relative excess response in
lung function parameters from baseline for the
various ambient acrolein concentrations are
presented in Table 3. Using the linear model
derived from the BMDS, we estimated a
0.53% decrease in sCL associated with median
acrolein concentrations, compared with esti-
mates for those without exposure to acrolein.
This decrease was 0.65% at the median con-
centration in urban counties and 0.14% at the
median in rural counties. The estimated per-
cent decrease in sCL for those in the 5th to the
95th percentiles of acrolein concentration dis-
tribution was 0.06–2.8% for all counties. For
RV/TLC, we estimated a 0.0004% increase
associated with median acrolein concentra-
tions; the increase at the 95th percentile of
acrolein concentration was 0.034%.
Discussion 
This exploratory analysis goes beyond compari-
sons of ambient concentrations to a reference
concentration, instead providing estimates of
the number of individuals who may be
adversely affected. Acrolein is of particular
interest because of indications that much of
the U.S. population is routinely exposed to
concentrations of acrolein greater than the
RfC for this pollutant. We found an estimated
median of 2.5 and 0.002 excess cases per
1,000 for additional adverse outcomes in sCL
and RV/TLC, respectively. 
Lung function impairments are closely
related to the manifestation of chronic respira-
tory disease. Both RV and TLC measurements
increase with increasing acrolein exposure,
indicating increasing lung volumes. An
increase in the RV/TLC ratio suggests that a
reduced volume of air is expired. These are
consistent with lung function changes seen in
obstructive lung diseases, such as asthma,
chronic bronchitis, and emphysema (Hlastala
and Berger 1996). 
Increased lung volume measures are also
consistent with decreased compliance
(Hlastala and Berger 1996). In their original
study, Costa et al. (1986) noted an increase in
lung collagen. Increased collagen deposition is
part of the airway remodeling process found in
chronic asthma; this leads to the narrowing of
the airways and potentially reduced airway
compliance (Bai and Knight 2005; Haahtela
2001). It is plausible that acrolein exposure
could affect collagen deposition; recent work
has demonstrated that exposure to other
highly reactive airborne toxicants, specifically
ozone, alters the expression of fibroblast
growth factors (Evans et al. 2003). Reduced
airway compliance—in our analysis, measured
as sCL—may be a compensatory mechanism
in response to airway narrowing (Bai and
Knight 2005). 
Because there were very limited human
data available, we modeled lung function
responses on toxicologic data in rats. It is pos-
sible that acrolein will act in a different
physiologic manner in humans and rats,
because rats (unlike humans) are obligate
nasal breathers. Thus, we do not interpret the
lung function measures from the rat study
(sCL and RV/TLC) to strictly correspond to
specific effects in human lungs. Rather, we
take these measured specific effects as more
general indicators of potential for decrements
in human lung function. Adversity encom-
passes a range of functional impairment; the
U.S. EPA Integrated Risk Information System
(U.S. EPA 2005b) defines an adverse effect as
“a biochemical change, functional impair-
ment, or pathologic lesion that affects the per-
formance of the whole organism, or reduces
an organism’s ability to respond to an addi-
tional environmental challenge.” The multiple
effects of acrolein on lung function indicate
that there are a constellation of changes to
lung function measurements consistent with
the potential for adverse effects in humans. An
alternate approach to our analysis would have
been to model the end points as a group,
because acrolein appears to lead to multiple
effects on the lung. In this case, the approach
we took in this analysis would lead to poten-
tially underestimating the effects of acrolein
exposure. 
Consideration of individual susceptibility
is also important. Individuals with existing res-
piratory impairment, such as chronic obstruc-
tive pulmonary disease or asthma, are more
likely to exhibit adverse responses to irritants
such as acrolein, and at potentially lower levels
of exposure. Certain subpopulations (e.g.,
women, children, the elderly) may react differ-
ently following acrolein exposure, and our
study uses data from healthy adult rats. The
choice of a 10% rate of adverse effects in an
unexposed population somewhat accounts for
a susceptible portion of the population (e.g.,
9% of children currently have asthma in the
United States) [Federal Interagency Forum on
Child and Family Statistics (FIFCFS) 2005] as
well as the adjustments to the continuous
exposure. 
To estimate risks for continuous end
points, it is necessary to define a response
level considered adverse or abnormal. This
can be challenging because continuous
Estimating risk from ambient acrolein
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Table 3. Percent change in lung function parameters above background for the range of modeled acrolein
concentrations across the United States, 1999.
Percent changea
Acrolein concentration (µg/m3) Percentileb sCL RV/TLC
0.0087 5 –0.060 1.4 × 10–6
0.034 25 –0.23 5.0 × 10–5
0.077 50 –0.53 4.3 × 10–4
0.14 75 –0.96 2.1 × 10–3
0.41 95 –2.8 3.4 × 10–2
RfCc –0.14 1.25 × 10–5
aPercent change in lung function parameter is defined as the [parameter (exposed) – parameter (unexposed) (baseline)]
÷ [parameter (baseline)] × 100; parameters are estimated from the regression equations presented in Table S1
(Supplemental Material available online at http://www.ehponline.org/docs/2006/9467/suppl.pdf). bPercentile of estimated
acrolein concentration distribution across all census tracts. cThe current RfC for acrolein is 0.02 µg/m3.
measurements of physiologic function capture
both levels considered normal and those con-
sidered adverse. In some cases, any change
above the background rate is considered
adverse, as has been used in the U.S. EPA draft
dioxin risk assessment (U.S. EPA 2004) for
several outcomes such as thyroid function,
immune or developmental effects, and enzyme
(CYP1A1/1A2) induction. In other cases, a
specific point estimate has been designated as a
cutoff level for adverse responses: for example,
obesity has been defined as a body mass index
of ≥ 30.0 on the basis of studies that found a
high risk for type 2 diabetes and cardiovascular
disease in adults with a body mass index > 30
(National Institutes of Health 2000). Another
method, the one used here, is to define adverse
outcomes as at or above a specified percentile
response of the baseline population. We chose
the 90th percentile of controls as a reasonable
definition of a baseline adverse response in the
ratio of lung function parameters based on
consideration of other health effects in humans
(e.g., small for gestational age infants are
defined as the 10th percentile of birth weight
for gestational age), but more or less conserva-
tive choices for the cutoff do not substantially
alter the estimated excess risks. 
A separate analysis of combined estimated
excess cancer risk for the identified carcino-
genic hazardous air pollutants, using tradi-
tional cancer risk methods, found a median
estimate of approximately two lifetime cases
per 10,000 people exposed (Woodruff et al.
2000). Many of the assessments underlying
the cancer risk estimates for hazardous air pol-
lutants are based on a more robust literature
(e.g., extensive occupational studies) than is
available for acrolein. Comparing the amount
of available data for these compounds sug-
gests that further research on the health
effects of acrolein would be useful to elucidate
its potential risks. 
Risk assessments for effects other than can-
cer generally rely on comparisons of estimated
exposure levels to reference doses or reference
concentrations. Although there are some
exceptions for environmental contaminants
with extensive epidemiologic data, noncancer
risk assessments using laboratory animal data
are almost exclusively based on the reference
dose (RfD)/RfC model. Reliance on the
RfD/RfC model has been based on the
assumption that there exists a threshold of
exposure for toxic chemicals, below which
there is no appreciable risk (U.S. EPA 2002b).
However, Clewell and Crump (2005) recently
argued that the uncertainties involved at low
doses for noncancer effects are no greater than
those for the customary extrapolations used in
cancer risk assessment, and that linear extrapo-
lation of risks to low doses for noncancer
effects is appropriate to inform regulatory
decision-making (Clewell and Crump 2005).
There are several aspects of cancer and
noncancer health effects associated with expo-
sure to toxic chemicals that are similar and
that support treating these health effects the
same way from a risk-assessment perspective.
The linear no-threshold model, frequently
used in assessing excess cancer risk, is based
on a number of biological assumptions. One
is that the exposure to the carcinogen is
adding to already existing biological processes
(Clewell and Crump 2005). Given an appre-
ciable background incidence of cancer in the
human population and in control animals,
there are other ongoing biological processes
that independently contribute to the excess
risk of cancer, and chemical exposures can
enhance what is already occurring biologi-
cally. Another assumption is that exposure to
an individual chemical is occurring in addi-
tion to other simultaneous or preexisting
exposures to other chemicals (Crump et al.
1976). This other background exposure can
contribute to the risk of cancer prior to expo-
sure to the carcinogen of interest. If a carcino-
gen is thought to have a threshold in a
scenario in which there are no other factors
contributing to the development of cancer,
the biological background and background
exposures that occur in more realistic scenar-
ios can effectively raise the starting point on
the dose–response curve above any theoretical
threshold. There is no reason to believe that
exposures to chemicals for noncancer effects
would act drastically differently. Several non-
cancer diseases have appreciable background
incidence in the population (e.g., cardio-
vascular effects, respiratory effects, reproduc-
tive effects), and the exposure to a particular
chemical being assessed adds to existing expo-
sures to other toxic chemicals. Therefore,
exposures to chemicals with noncancer effects
are likely to have the effect of shifting the
response distribution, as shown in Figure 1. 
In the particular example of the present
acrolein analysis, respiratory conditions such as
asthma are already at an appreciable level in the
population. In addition, acrolein exposures
occur simultaneously with exposure to other
air pollutants, many of which are ubiquitous
and have been demonstrated to cause respira-
tory effects (e.g., ozone and particulate matter).
This analysis is consistent with the suggestion
of Clewell and Crump (2005) that estimation
of excess risks for noncancer effects could be
conducted and presented in a manner similar
to the analyses that have been conducted for
potential carcinogens on a regular basis over
the last two decades. 
It is also important to consider how far
the response is being extrapolated below the
data. The greater the extrapolation, the
greater its associated uncertainty. Mean and
median national ambient acrolein exposures
are 8.7 and 6.2 times lower, respectively, than
the lowest HEC-converted dose used in this
analysis. This is not a substantial extrapola-
tion below the low end of the data, and we
would not expect the shape of the curve to
change drastically in this range. However,
there is some increased uncertainty from esti-
mating shifts at the tails of the distribution of
response, which could be more uncertain
than estimating shifts in the median of
response. This is due to smaller numbers of
responses at the ends of the distribution, and
a change in response in a small number of
animals at the ends of the distribution could
have a relatively larger impact on the estimate
of the 90th percentile in response. 
A potential source of error in the risk esti-
mate is the data transformation process. By
transforming noncontinuous, 62-day exposures
into continuous, yearly exposures, we assume
that measured responses are independent of
timing and intensity of exposure. The adjust-
ments used in this analysis essentially assume
that the response would occur at proportion-
ally lower exposures if the exposures had been
continuous over a year. Changing our assump-
tions would naturally alter our outcomes. Two
examples of this are a) adjusting the 62-day
exposure time to a 90-day period (the usual
subchronic period) instead of a 365-day
period; or b) adjusting to a 90-day subchronic
period and also applying a 10-fold uncertainty
factor to account for potential differences
between subchronic and chronic exposures. If
we had adjusted the exposure duration to stan-
dard subchronic length, the slope of the dose–
response relationship between predicted
adverse responses and exposures would be
about 4 times lower (i.e., less steep). This
would reduce the amount of predicted risk.
However, if we had adjusted exposures to sub-
chronic durations and then applied a 10-fold
uncertainty factor to account for adjusting
from subchronic to chronic exposures, this
slope would be about 2.5 times higher than we
estimated (i.e., a steeper dose response); thus,
using an uncertainty factor on a subchronic
exposure measure would increase the predicted
risk. The transformation method we selected is
therefore well within a plausible range.
The excess risks presented here are based
on estimated ambient outdoor exposures; how-
ever, indoor acrolein levels can be 2–20 times
higher than outdoor concentrations, especially
in areas with high levels of environmental
tobacco smoke (U.S. EPA 2003b). Because
most individuals spend the majority of their
time indoors (Klepeis et al. 2001; Weisel
2002), excess risks from acrolein exposure
could well be higher than those predicted here. 
The present analysis provides an exam-
ple of how a noncancer risk assessment
could be undertaken using a dose–response,
nonthreshold model, similar to standard
approaches for cancer risk assessment. This
Woodruff et al.
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type of analysis is not likely to involve more
uncertainty than recommended methods for
cancer risk assessment, and it has the poten-
tial to provide more detailed information
than traditional noncancer risk assessments.
Using this method, we found that ambient
acrolein levels may be contributing to
decreased respiratory function. These results
suggest increased use of nonthreshold models
for noncancer risk assessment should be
explored further.
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